Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226317 · ClinicalTrials.gov registry record · NA
Aripiprazole in the Treatment of Bipolar Depression
A NA study, sponsored by Cambridge Health Alliance.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT00226317 is a NA study that has completed, run by Cambridge Health Alliance. The registered enrollment target is 20 participants.
The verdict
NCT00226317, a NA study, has completed, sponsored by Cambridge Health Alliance.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
A systematic open-label prospective pilot study to assess aripirazole for acute bipolar depression, with a secondary assessment of longer-term mood stabilization.
Interventions
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-04 |
| Est. Completion | 2008-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00226317
The ClinicalTrials.gov registry entry for NCT00226317 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cambridge Health Alliance, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00226317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00226317 about?
NCT00226317 is a clinical study titled "Aripiprazole in the Treatment of Bipolar Depression". A systematic open-label prospective pilot study to assess aripirazole for acute bipolar depression, with a secondary assessment of longer-term mood stabilization.
What is the current status of trial NCT00226317?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2004-04. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00226317?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00226317?
This trial is sponsored by Cambridge Health Alliance, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.